Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-25T02:12:11.598Z Has data issue: false hasContentIssue false
  • English
  • Français

Review of recent clinical studies with olanzapine

Published online by Cambridge University Press:  06 August 2018

Gary D. Tollefson  and
Amy J. Kuntz
Gary D. Tollefson*
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Amy J. Kuntz
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
*
Correspondence: Dr G. D. Tollefson, Vice President, Lilly Research Laboratories, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments. Clinical investigations employing olanzapine have demonstrated a number of potential therapeutic advantages in reference not only to placebo but also to contemporary drug standards in the management of psychosis. This paper reviews data on the pharmacokinetics, efficacy and safety of olanzapine, its benefits for quality of life, and economic aspects to assist clinicians in determining where they can usefully employ it.

Type
Review Article
Information
The British Journal of Psychiatry , Volume 174 , Issue S37: Focus on schizophrenia , February 1999 , pp. 30 - 35
Copyright
Copyright © The Royal College of Psychiatrists, 1999 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, N. C. (1982) Negative symptoms in schizophrenia. Archives of General Psychiatry, 39, 784–788.CrossRefGoogle ScholarPubMed
Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.Google Scholar
Beasley, C. M., Jr, Sanger, T., Satterlee, W., et al (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159–167.Google Scholar
Beasley, C. M., Tollefson, G. D., Tran, P. V., et al (1996b) Olanzapine versus placebo and haloperidol: acute-phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 105–118.Google Scholar
Beasley, C. M., Hamilton, S. H., Crawford, A. M., et al (1997a) Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125–137.Google Scholar
Beasley, C. M., Tollefson, G. D. & Tran, P. V. (1997b) Efficacy of olanzapine: an overview of pivotal clinical studies. Journal of Clinical Psychiatry, 58 (suppl. 10), 7–12.Google Scholar
Crawford, A. M. K., Beasley, C. M. Jr & Tollefson, G. D. (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26, 41–54.Google Scholar
Dellva, M. A., Tran, P., Tollefson, G. D., et al (1997) Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services, 48, 1571–1577.Google ScholarPubMed
Glazer, W. M. (1997) Olanzapine and the new generation of antipsychotic agents: patterns of use. Journal of Clinical Psychiatry, 58 (suppl. 10), 18–21.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (revised version). Bethesda, MD: US Department of Health, Education and Welfare.Google Scholar
Harrow, M., Yonan, C. A., Sands, J. R., et al (1994) Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophrenia Bulletin, 20, 327–338.Google Scholar
Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. (1984) The Quality of Life Scale: an instrument for rating schizophrenia deficit syndrome. Schizophrenia Bulletin, 10, 388–398.Google Scholar
Kay, S. R., Opler, L. A. & Fiszbein, A. (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems Inc.Google Scholar
Nemeroff, C. B. (1997) Dosing the antipsyc hotic medication olanzapine. Journal of Clinical Psychiatry, 58 (suppl. 10), 45–49.Google Scholar
Pilowsky, L. S., Busatto, G. F., Taylor, M., et al (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine – a 1231 1BZM single photon emission tomography (SPET) study. Psychopharmacology, 124, 148–153.Google Scholar
Tollefson, G. D. & Sanger, T. M. (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466–474.Google Scholar
Tollefson, G. D., Beasley, C. M., Jr, Tamura, R. N., et al (1997a) A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248–1254.Google ScholarPubMed
Tollefson, G. D., Beasley, C. M., Tran, P. V., et al (1997b) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
Tollefson, G. D., Tran, P. V., Birkett, M., et al (1997c) Treatment failure with clozapine. Can olanzapine be the alternative therapy? Schizophrenia Research, 24, 191.Google Scholar
Tollefson, G. D., Sanger, T. M., Lu, Y., et al (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry, 55, 250–258.CrossRefGoogle ScholarPubMed
Tran, P. V., Hamilton, S. H., Kuntz, A. J., et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407–418.Google Scholar
Woerner, M. G., Mannuzza, S. & Kane, J. M. (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin, 24, 112–117.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.